Welcome to our dedicated page for Avantor SEC filings (Ticker: AVTR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Avantor's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Avantor's regulatory disclosures and financial reporting.
Avantor, Inc. (AVTR) reported a Q3 2025 net loss of $711.8 million, driven by a non‑cash, non‑deductible $785.0 million goodwill impairment in its Distribution reporting unit. Net sales were $1,623.8 million, down 5.3% year over year as organic net sales decreased 4.7%. Gross profit was $526.5 million and operating loss was $648.8 million.
Adjusted Operating Income was $237.3 million for the quarter, with Laboratory Solutions at $123.6 million and Bioscience Production at $127.7 million. Year‑to‑date, net cash provided by operating activities was $471.1 million. On the balance sheet, total assets were $11,675.9 million and total debt was $3,857.9 million.
During the quarter, the company made an optional prepayment of $457.4 million on its 2.625% secured notes. Subsequent to quarter‑end, Avantor issued €400.0 million and €550.0 million senior secured term loans (maturing in 2030 and 2032) and amended its revolving credit facility to $1,400.0 million. The Board authorized up to $500.0 million of common stock repurchases.
Avantor, Inc. filed a current report to note that it released a press release with its financial results for the quarter ended September 30, 2025. The press release was issued on October 29, 2025 and is attached as Exhibit 99.1.
The company states that the information in this report, including Exhibit 99.1, is being furnished under Item 2.02 (Results of Operations and Financial Condition) and is not deemed filed for liability purposes under the Securities Exchange Act.
BlackRock, Inc. filed Amendment No. 5 to Schedule 13G reporting beneficial ownership of Avantor, Inc. common stock. BlackRock reports 59,049,575 shares beneficially owned, representing 8.7% of the class as of the event date 09/30/2025.
BlackRock has sole voting power over 56,188,076 shares and sole dispositive power over 59,049,575 shares, with no shared voting or dispositive power. The filing states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control.
Avantor, Inc. amended its senior secured credit facilities to bolster liquidity and extend maturities. The Amended Credit Agreement adds replacement and incremental revolving credit commitments totaling $1.4 billion, a new €400 million Incremental Euro Term A Loan, and a new €550 million Incremental B‑6 Euro Term Loan. The revolving facility and Term A mature on October 9, 2030, and the Term B on October 9, 2032.
Proceeds will repay or refinance existing secured debt, including the accounts receivable securitization and remaining first‑lien notes, cover related fees, and provide additional liquidity. On the Termination Date, approximately $208 million outstanding under the up to $300 million A/R Facility was repaid in full and the facility was terminated. The Borrower redeemed €400 million of 2.625% Senior First Lien Notes on August 29, 2025 and the remaining €250 million on October 10, 2025.
The Term B loan bears interest at benchmark plus 2.50%. Obligations are guaranteed by substantially all wholly owned domestic subsidiaries (excluding the Company) and are secured by substantially all assets, subject to customary exceptions, with customary covenants and events of default.
Avantor, Inc. announced that Jonathan Peacock will step down as chairman, director, and member of the Nominating and Governance Committee on December 31, 2025. The company stated his decision was not due to any disagreement regarding its operations, policies, or practices.
Current director Gregory L. Summe will serve as the next chairman effective January 1, 2026. The transition details were also provided in a press release furnished under Regulation FD.
Avantor, Inc. director Gregory T. Lucier received a grant of 8,736 restricted stock units (RSUs) on 10/03/2025 that vest one year later on 10/03/2026. The grant was reported on a Form 4 filed by a single reporting person and shows an acquisition with a reported price of $0, consistent with equity awards issued as compensation rather than an open-market purchase. After the grant Lucier beneficially owns 8,736 shares of common stock directly. The Form 4 signature was executed by an attorney-in-fact on 10/07/2025.
Gregory T. Lucier, identified as a director of Avantor, Inc. (AVTR), submitted an initial Form 3 reporting that he does not beneficially own any Avantor securities. The filing lists the reporting person’s Radnor, PA business address and indicates the form was executed via an attorney‑in‑fact. There are no listed non‑derivative or derivative holdings attached to this statement.
Avantor (AVTR) insider filing: The company’s EVP, Bioscience Production reported a Form 4 transaction on 10/02/2025. The filing shows 1,264 shares of common stock were withheld by the issuer at $13.77 under code F, which reflects shares retained to satisfy tax withholding in connection with RSU vesting. Following this administrative withholding, the reporting person directly holds 235,684 shares.
Avantor, Inc. reported that its Board of Directors elected Gregory Lucier as a director, effective October 3, 2025, with an initial term running until the 2026 Annual Meeting of Stockholders. The Board determined he meets New York Stock Exchange and Exchange Act independence standards.
Lucier is Executive Chairman and CEO of Corza Medical and previously led NuVasive and Life Technologies, with earlier leadership roles at General Electric. He will receive Avantor’s standard non-employee director compensation, including a prorated $95,000 annual cash retainer and restricted stock units with a grant date fair value of $210,000, vesting in full one year after grant. Avantor also issued a press release announcing his election, furnished as Exhibit 99.
Avantor director Gregory L. Summe, through a trust, executed an open-market purchase of 100,000 shares of Common Stock at a weighted average price of $12.56 per share. The shares were bought in multiple trades between $12.50 and $12.63.
Following this transaction, the trust holds 200,000 Avantor shares indirectly attributed to Summe, while he also directly holds 58,111 shares. He reports beneficial ownership of the trust’s shares but disclaims beneficial ownership beyond his pecuniary interest.